Arrowhead Pharmaceuticals General and Administrative Expenses 2011-2026 | ARWR

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Arrowhead Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
124 M	98.8 M	92.5 M	124 M	81 M	52.3 M	26.6 M	19.1 M	32 M	41 M	34.7 M	24.4 M	11.7 M	14.1 M	5.23 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
124 M	5.23 M	52.1 M

Quarterly General and Administrative Expenses Arrowhead Pharmaceuticals

2025-Q4	2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
46 M	-	30.9 M	26.9 M	-	23.7 M	25.1 M	23.6 M	-	23.8 M	23.2 M	21 M	-	33.1 M	34.3 M	25 M	-	18.4 M	16.3 M	8.8 M	38 M	10.7 M	8.8 M	10.9 M	16.3 M	4.81 M	10.9 M	6.14 M	12.7 M	4.59 M	6.14 M	4.4 M	12.1 M	3.92 M	1.67 M	1.85 M	8.05 M	2.28 M	1.85 M	1.95 M	5.61 M	1.83 M	1.95 M	2.09 M	3.87 M	1.58 M	2.09 M	914 K	2.6 M	900 K	914 K	918 K	5.34 M	3.14 M	918 K	1.27 M	2.08 M	637 K	1.28 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
46 M	637 K	10.9 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Aquestive Therapeutics AQST	79.8 M	$ 4.14	0.36 %	$ 443 M	USA
Arcturus Therapeutics Holdings ARCT	46.1 M	$ 8.41	4.73 %	$ 230 M	Israel
Ardelyx ARDX	337 M	$ 6.06	1.94 %	$ 1.46 B	USA
argenx SE ARGX	308 M	$ 752.35	0.79 %	$ 25 B	Niderland
Arcutis Biotherapeutics ARQT	275 M	$ 23.83	0.85 %	$ 3.03 B	USA
Aytu BioScience AYTU	17.4 M	$ 2.65	-1.12 %	$ 16.6 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
BioCardia BCDA	3.32 M	$ 1.2	-0.04 %	$ 8 M	USA
BioCryst Pharmaceuticals BCRX	266 M	$ 9.6	6.37 %	$ 1.98 B	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	714 M	$ 9.48	-3.27 %	$ 613 M	USA
BioVie BIVI	8.57 M	$ 1.45	2.09 %	$ 2.14 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
BioLineRx Ltd. BLRX	4.31 M	$ 2.32	4.98 %	$ 908 M	Israel
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
BioMarin Pharmaceutical BMRN	1.15 B	$ 56.49	1.78 %	$ 10.8 B	USA
BioNTech SE BNTX	286 M	$ 92.3	1.23 %	$ 27.2 B	Germany
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	10.9 M	-	10.36 %	$ 9.8 M	USA
Anavex Life Sciences Corp. AVXL	13.8 M	$ 3.04	1.54 %	$ 259 M	USA
BioXcel Therapeutics BTAI	20.5 M	$ 1.16	-2.12 %	$ 14.2 M	USA
Burford Capital Limited BUR	99.3 M	$ 4.54	9.54 %	$ 683 M	Britain
Cabaletta Bio CABA	29.6 M	$ 3.2	7.94 %	$ 322 M	USA
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 3.21	4.56 %	$ 6.98 B	Israel
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Catalyst Biosciences CBIO	20.8 M	$ 19.97	2.94 %	$ 1.78 B	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Codexis CDXS	47.1 M	$ 1.97	7.97 %	$ 172 M	USA
Cerus Corporation CERS	80.9 M	$ 1.91	2.42 %	$ 364 M	USA
Cullinan Management CGEM	54.2 M	$ 15.4	6.72 %	$ 928 M	USA
Coherus BioSciences CHRS	101 M	$ 1.75	0.87 %	$ 205 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain